We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Warning Claim, Punitives Survive Dismissal In Invokana Ketoacidosis Case

(August 3, 2016, 12:49 PM EDT) -- ROME, Ga. — A Georgia federal judge on July 11 dismissed most claims by a plaintiff that the diabetes drug Invokana caused her diabetic ketoacidosis but said her failure-to-warn claims survive (Paula Brizil v. Janssen Research & Development LLC, et al., No. 15-204, N.D. Ga., Rome Div.; 2016 U.S. Dist. LEXIS 93528).

(Opinion available. Document #28-160804-015Z.)

Invokana is a diabetes drug of the sodium glucose co-transporter 2 (SGLT2) inhibitor class. It is prescribed to patients with type 2 diabetes to help control their blood glucose....
To view the full article, register now.